Loading
Latest filing published 02 Jan 2026 for Oramed Pharmaceuticals INC.. Read the official filing
No signal scores available.
Daniel Aghion discloses dealings in Oramed Pharmaceuticals Inc. to SEC (Form 4). In total, 4 filings cover trades dated from 4 January 2024 to 31 December 2025.
The filings describe grants, exercises and other transfers rather than trades on the open market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
The latest filing, published on 2 January 2026, reports a share grant in Oramed Pharmaceuticals Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations